Anti-Her2 therapy patterns in metastatic breast cancer-Real-world data suggest undertreatment.

ABSTRACT: Treatment efficacy of anti-HER2 therapies for metastatic breast cancer (mBC) has been demonstrated in clinical trials, but real-world data are lacking. In particular, it is unclear whether patients in clinical practice receive treatment as recommended. We took advantage of population-based registries in Norway to assess anti-HER2 therapy patterns in real-world data, with specific attention to the treatment of vulnerable groups. We included 715 patients with HER2+ mBC diagnosed from 2012 to 2021. Median age was 60 years, 473 (66%) had relapsed from early-stage BC, and 440 (62%) had hormone receptor positive (HR+) disease. Anti-HER2 therapy patterns aligned with national recommendations. Median treatment duration for first line therapy was 7.2 months, where 261 patients (55%) used trastuzuma

SUBMITTER: Vandraas KF 

PROVIDER: S-EPMC12670336 | biostudies-literature | 2026 Feb

REPOSITORIES: biostudies-literature